

REMARKS**1. Rejection of Claim 18 under 35 USC §112(2) and §101**

This rejection should be withdrawn for the grounds noted at Section 1 of the Response dated August 10, 2005:

Kindly withdraw this rejection, which is predicated on the basis that "the claim does not set forth any steps involved in the method/process...." However, note that claim 18 positively recites the step of "*applying topically to the affected area* an effective amount...." Further, while the rejection states that "'the use of' is not a statutory class of invention", we assert that the claim is an acceptable method/process claim reciting positive steps; see, e.g., MPEP 706.03(a), which notes that "[t]he term 'process' as defined in 35 USC 100, means process, art or method, *and includes a new use* of a known process, machine, manufacture, composition of matter, or material" (emphasis added). Here, since steps are recited, and a "use" is merely a method/process by another name, we submit that claim 18 meets all requirements of 35 USC §112(2).

Note that while the Final Office Action responds that the recitation of the "use of" a substance will not constitute a proper method claim (page 9 of the Final Office Action), the Office Action does not address why the "applying topically" step – a positively-recited step – does not make claim 18 an acceptable method claim. If the rejection is maintained, please address and respond to these arguments.¹

¹ See MPEP 707.07(f), Answer All Material Traversed ("Where the applicant traverses any rejection, the examiner should, if he or she repeats the rejection, take note of the applicant's argument and answer the substance of it"); also see Examiner Notes for PTO form paragraphs 7.37 and 7.38 (as reproduced in MPEP 707.07), which require that all relevant arguments by the Applicant be addressed, as well as MPEP 706.07 under "Statement of Grounds" ("the final rejection . . . also should include a rebuttal of any arguments raised in the applicant's reply").

2. Rejection of Claims 14-17 under 35 USC §103(a) in view of U.S. Patent 4,879,282 to Saliba and U.S. Patent 5,874,094 to Costello

Kindly reconsider these rejections, which are founded on an improper *per se* rule of obviousness at pages 4 and 5 of the Office Action, wherein it is stated:

It would have been obvious to one having ordinary skill in the art, at the time the claimed invention was made, in view of Saliba, Jr and Costello, to have used the method of Saliba, Jr to treat insect bites with a composition comprising a combination of sodium heparin and zinc oxide, since the combination of compounds that are used to treat the same diseases or condition are well known in the art. More specifically, it is obvious to combine individual compositions taught to have the same utility to form a new composition for the very same purpose. *In re Kerkhoven*, 626 F.2d 846, 205 U.S.P.Q. 1069 (C.C.P.A. 1980).

This is an improper use of a *per se* rule of obviousness, i.e., relying on a holding in a prior case based on different facts to the current case. This approach is incorrect because it fails to make the fact-intensive inquiry mandated by §103, and it does not show where the prior art would truly motivate or suggest one of ordinary skill in the art to make the asserted modification or combination. The Court of Appeals for the Federal Circuit has explicitly forbidden the use of *per se* rules in *In re Ochiai*, 37 USPQ2d 1127 (Fed. Cir. 1995):

The use of *per se* rules, while undoubtedly less laborious than a searching comparison of the claimed invention -- including all its limitations -- with the teachings of the prior art, flouts section 103 and the fundamental case law applying it. *Per se* rules that eliminate the need for fact-specific analysis of claims and prior art may be administratively convenient for PTO examiners and the Board. Indeed, they have been sanctioned by the Board as well. But reliance on *per se* rules of obviousness is legally incorrect and must cease. Any such administrative convenience is simply inconsistent with section 103, which, according to Graham and its progeny, entitles an applicant to issuance of an otherwise proper patent unless the PTO establishes that the invention as claimed in the application is obvious over cited prior art, based on the specific comparison of that prior art with claim limitations. We once again hold today that our precedents do not establish any *per se* rules of obviousness, just as those precedents themselves expressly declined to create such rules. Any conflicts as may be perceived to exist derive from an impermissible effort to extract *per se* rules from decisions that disavow precisely such extraction.

Id. at 1133. See also *Litton Systems Inc. v. Honeywell Inc.*, 39 USPQ2d 1321, 1325 (Fed. Cir. 1996) ("As we expressly recognized in *Ochiai*, the obviousness inquiry is highly fact-specific and not susceptible to *per se* rules. The Supreme Court has underscored the fact intensive nature of the test for obviousness.").

Further, we respectfully submit that much of the reasoning underlying the rejections is erroneous in that it seems founded on the proposition that one *could* combine *Saliba* and *Costello* to attain the claimed compositions/methods rather than that the prior art suggests that one *should* modify the references to attain the claimed matter, setting forth statements such as:

- "this does not mean that concentrations outside this range will not be efficacious or effective although they may not be most efficacious" (page 7, emphasis in original);
- "this does not imply that the carrier has to be at an acidic pH to be efficacious or effective, but only to be most efficacious" (page 7, emphasis in original);
- "this does not mean that concentrations outside this range will not be efficacious or effective although they may not be most efficacious" (page 8, emphasis in original);
- "However, *Saliba* does not plainly suggest or vaguely suggest that one *cannot* add materials such as zinc oxide to heparin when used topically (as claimed). Firstly, *Saliba* does not suggest that zinc oxide is a carrier nor that zinc oxide or other compounds *cannot* be combined or added to heparin. Furthermore, *Saliba* does not suggest that compounds with pH's that are not acidic *cannot* be combined with heparin." (page 8, emphasis added).

However, these are not proper tests for obviousness. The obviousness inquiry is not properly addressed by asking whether an invention is *unobvious* only if the prior art references show or suggest that the claimed combination is *not* feasible or beneficial. Rather, the obviousness inquiry requires that one determine if the prior art references suggest that one *should* combine or modify features of a prior composition/method to arrive at the claimed composition/method. Further, the

references must *clearly and affirmatively* suggest the claimed invention.² As explained below, while *Saliba* and *Costello* do describe use of ingredients used in the claimed composition, we believe that the references, when considered fully, fairly, and objectively, cannot be said to fairly suggest the claimed matter. Please give balanced and careful consideration to the following.

Initially, reviewing the teachings of the cited references, *Saliba* expresses that heparin is useful for treating a huge range of conditions, including ailments as diverse as poisonings, "space-travel sickness," electrical dysrhythmias of the nervous system, and stomach ulcers (see the Abstract and column 2 line 58 onward), as well as insect bites (see the foregoing, as well as column 7 lines 25-35) – and these ailments can be treated with either topical or injected heparin (see column 6 line 66-column 7 line 11). In essence, *Saliba* contends that heparin is effective when administered in almost any manner, to almost any ailment. *Saliba* also notes that when heparin is to be applied topically, it should be applied at concentrations of 1,500 IU - 5,000 IU per ml (see column 6 line 66 - column 7 line 35), and it should be accompanied by an acidic carrier (preferably with a pH of about 5.5); see column 7 lines 11-16.

Costello then discusses a topical cream using aloe vera as its key active ingredient, along with vitamin E and zinc oxide (see Abstract; column 3 lines 13-23). The cream contains 3-10 g of aloe vera, 200-900 IU (0.19-9.25 g) of vitamin E, and 0.4-1.5 g zinc oxide per ounce (an ounce being 28.47 g); see column 4 lines 29-36. This equates to a cream containing 10-15% aloe vera, 0.67-32% vitamin E, and 1.4-5.2% zinc oxide (by weight).

When the presently claimed invention is placed out of mind, and the cited references are objectively considered for all they suggest, it cannot fairly be said that one of ordinary skill would be led to combine them to obtain the claimed invention. Initially, even if one regarded *Saliba*'s

²See, e.g., *Winner International Royalty Corp. v. Wang*, 53 USPQ2d 1580, 1586 (Fed. Cir. 2000) (citations and footnotes omitted):

When an obviousness determination is based on multiple prior art references, there must be a showing of some "teaching, suggestion, or reason" to combine the references. Although a reference need not expressly teach that the disclosure contained therein should be combined with another, the [1587] showing of combinability, in whatever form, must nevertheless be 'clear and particular.'"

assertion of heparin-based insect bite treatment as credible, *Saliba* suggests use of heparin in a far greater amount than the amount claimed: 1,500-5,000 IU per milliliter, as compared to the 100-300 USP (IU) per gram claimed. The Examiner notes that the claimed composition and *Saliba* have different units (*Saliba* using 1,500-5,000 IU/ml and the claimed composition using 300 IU/g), and thus the two measures are not fully comparable, but consider that most aqueous substances have close equivalence between milliliter volume and gram mass (water having a volume of 1 ml per gram). Thus, even if it is assumed that the claimed range would be closer to the *Saliba* range if expressed in the same units, the ranges are still vastly different, with *Saliba* suggesting the use of *five to fifty times* the amount of heparin used in the claimed composition.

Further, *Saliba* does plainly suggest against the use of materials such as zinc oxide, which are fundamentally basic to neutral in pH,³ with heparin, at least when used topically (as claimed); for example:

The uses are realized by applying the [heparin] compounds either in solution, or in the form of a cream or aerosol, preferably at a pH of about 5.5, in an effective amount and for a time sufficient to effect treatment.

(Abstract.) Also see column 7 lines 11-16:

I have found that for topical applications of heparin, it is most efficacious to apply the solution in a carrier having an acidic pH and particularly a pH of about 5.5. For reasons that are presently unknown, the medically beneficial uses of heparin are most apparent at acid pH's. Without wishing to be restricted to a particular mode of action of heparin as applicable to the instant invention, it is likely that this pH is favored because heparin interacts with and inactivates molecules involved in an inflammatory reaction, particularly histamine and serotonin and proteolytic enzymes most effectively at acid pH's. Since histamine is known to effect cellular destruction, its inhibition likely facilitates wound healing.

Also column 7 lines 42-44:

Again, it should be stressed that such compositions preferably have an acidic pH at the site of injury, and particularly a pH of about 5.5.

The Office Action states that "this does not imply that the carrier has to be an at acidic pH to be efficacious or effective, but only to be **most efficacious**" (Office Action, page 7). However, these

³ As noted in references submitted in the prior Response, zinc oxide has a pH of 6.95-7.37.

passages also plainly do not imply that there is *any benefit* to the addition of a basic material such as zinc oxide to heparin – and the proper test for obviousness is whether the prior art teaches some benefit, or provides some other motivation, to combining or modifying the prior art references.⁴ Please objectively consider the foregoing passages: can it fairly be said that these would lead an ordinary artisan who is seeking to improve the primary reference (*Saliba*) to use a neutral to basic material (such as zinc oxide) with heparin? We submit that if *Saliba* is fairly and objectively considered, the answer is no.

The Office Action also states at page 7 that “applicant composition is not limited to any particular pH and in fact applicant’s claimed carrier (carboxymethylcellulose carrier) should have an acidic pH.” But pH is not directly relevant to the independent claims 14, 16, and 18; rather, the pH values of the ingredients used alongside heparin are relevant to whether or not one would truly modify *Saliba*’s heparin compound to include basic ingredients such as zinc oxide. Further, carboxymethylcellulose is *not* in fact acidic – it is *basic*, with pH from 7-10 (see attached references). In fact, *all* of the recited carriers in claims 14, 16, and 18 are similarly substantially neutral to basic in character – which is directly contrary to *Saliba*’s suggestions.

The Office Action also *admits* at the bottom of page 8 of the Office Action that “*Saliba* suggests... that the heparin solution is most efficacious if an acidic carrier is used”, but then states that zinc oxide is not a carrier, and thus will not affect the pH of the solution wherein the heparin is carried. This is false; plainly all ingredients used alongside heparin in the composition are relevant to the *Saliba* pH, including zinc oxide as well as carriers, and thus one of ordinary skill would still find no motivation to add zinc oxide to heparin. Also, setting aside the issue of zinc oxide entirely, note that all of the carriers recited in Applicant’s independent claims 14, 16, and 18 are neutral to basic in character – which is directly contrary to the admitted suggestion of *Saliba*, and is thus further basis for unobviousness. Note that *Saliba*, while emphatic that the

⁴ See, e.g., MPEP 2143.01 under heading “THE PRIOR ART MUST SUGGEST THE DESIRABILITY OF THE CLAIMED INVENTION” (and conversely see under the heading “FACT THAT REFERENCES CAN BE COMBINED OR MODIFIED IS NOT SUFFICIENT TO ESTABLISH PRIMA FACIE OBVIOUSNESS”).

heparin should be combined with acidic carriers/ingredients, is otherwise quite vague as to the identity of the carriers/ingredients – but it is nevertheless clear that *Saliba*'s acidic carriers/ingredients do not overlap with Applicant's basic carriers/ingredients:

As alluded to above, a variety of pharmaceutical carriers can be employed with heparin to realize its beneficial uses. Such can be in liquid, solid or vapor form, and can be applied by injection, dripping, spreading or aerosol. A variety of solid pharmaceutical carriers can be imagined including starch, sugars, talc, manitol and the like. Again, it should be stressed that such compositions preferably have an acidic pH at the site of injury, and particularly a pH of about 5.5. It will be understood that the term carrier is meant to include, in addition to the above, buffered and non-buffered liquid.

(*Saliba* at column 7 lines 36-36.) In short, since Applicant's independent claims recite heparin used with zinc oxide and other neutral to basic carriers/ingredients, which is contrary to the admitted suggestion of *Saliba*, the compositions and methods recited in these claims cannot be said to be obvious.

In addition, even if it is assumed for the sake of argument that one *did* regard heparin and zinc oxide as combinable as per *Saliba* and *Costello*, these references also suggest use of a dramatically higher concentration of zinc oxide than the one claimed: *Costello* suggests use of 1.5-4.2 wt% zinc oxide, whereas the claimed invention calls for 1-20 mg/g (i.e., 0.001-0.02 wt%). Thus, even if one combined heparin and zinc oxide as per *Saliba* and *Costello*, the combination would not amount to the one claimed.⁵ This is particularly so when it is also considered that the *Saliba/Costello* combination would also have dramatically higher heparin than the claimed combination, as discussed above. The Office Action states at page 9 that "the use of different wt% of zinc oxide depends on factors like the severity of the insect bite, the type of

⁵ Please note that it appears this argument was not addressed in the Final Office Action. If the rejection is maintained, please address and respond to these arguments. See MPEP 707.07(f), Answer All Material Traversed ("Where the applicant traverses any rejection, the examiner should, if he or she repeats the rejection, take note of the applicant's argument and answer the substance of it"); also see Examiner Notes for PTO form paragraphs 7.37 and 7.38 (as reproduced in MPEP 707.07), which require that all relevant arguments by the Applicant be addressed, as well as MPEP 706.07 under "Statement of Grounds" ("the final rejection . . . also should include a rebuttal of any arguments raised in the applicant's reply").

subject treated and the other ingredients that comprises the composition such as heparin," but again this sidesteps the question of whether or not an ordinary artisan would truly find it obvious to construct the claimed composition from the cited references. *Costello* in no way suggests that more (or less) zinc oxide should be used depending on severity of the injury, and more fundamentally, *there is simply nothing that truly suggests that the claimed dramatically lower zinc oxide content should be used*. The sweeping statement that an ordinary artisan would simply choose any percentage of zinc oxide depending on the severity of injury simply does not ring true: how/why does *Costello* truly suggest that a dramatically lower zinc oxide content would be beneficial? Assuming that the Office Action's statement (that one would choose amount in accordance with the severity of injury), wouldn't one of ordinary skill use a *larger* percentage of zinc oxide, as in *Costello*, to account for a wide range of insect bites?

In summary, we submit that if the obviousness inquiry is properly addressed without the use of *per se* reasoning, and if one looks at *Saliba* and asks how an ordinary artisan *might fairly and objectively* be led to improve on *Saliba* in view of *Costello* and the other references of record, one would not arrive at the claimed composition/method. *Saliba* suggests that any ingredient added to a topical heparin composition should be acidic (unlike the claimed zinc oxide and carriers), and even if one did combine heparin and zinc oxide as per *Saliba* and *Costello*, the resulting combination would have vastly greater amounts of both heparin *and* zinc oxide than the combination claimed. Can it fairly be said that one of ordinary skill, after reviewing *Saliba* and *Costello*, would truly combine heparin with non-acidic ingredients (such as zinc oxide) and carriers, and use both heparin and zinc oxide in dramatically lower amounts? If the claimed invention is set out of mind, and *Saliba* and *Costello* are objectively reviewed for all that they suggest, it will be seen that this does not make sense. Rather, it is seen that one would, if anything and at most, use a topical mixture of *Saliba*'s heparin and *Costello*'s aloe vera: aloe is emphasized by *Costello* as being the key ingredient for *Costello*'s cream, and it has an acidic pH.⁶


⁶ As noted in references submitted in the prior Response, aloe is acidic.

But this is not the claimed invention. We therefore submit that claims 14-17 are novel, unobvious, and allowable in view of the cited references.

3. In Closing

If any questions regarding the application arise, please contact the undersigned attorney. Telephone calls related to this application are welcomed and encouraged. The Commissioner is authorized to charge any fees or credit any overpayments relating to this application to deposit account number 18-2055.

For the Applicant,



Craig A. Fieschko, Reg. No. 39,668
DEWITT ROSS & STEVENS, S.C.
Firststar Financial Centre
8000 Excelsior Drive, Suite 401
Madison, Wisconsin 53717-1914
Telephone: (608) 828-0722
Facsimile: (608) 831-2106

ATTACHMENTS:

- <http://www.chemicalland21.com/industrialchem/performancepolymer/CARBOXYMETHYL%20CELLULOSE%20SODIUM%20SALT.htm>

OFFICES
OFFICES

PRODUCTS > INDUSTRIAL CHEMICALS > PERFORMANCE POLYMERS

CARBOXYMETHYL CELLULOSE SODIUM SALT

PRODUCT IDENTIFICATION

COMMON NAME: 9004-32-4

SYNTHETIC NAME: C₆H₅OCH₂COONa

STRUCTURE: 391231

TOXICITY: Oral / rat LD₅₀: > 2000mg/kg

COMMON NAMES: CM-Cellulose sodium salt; Cellulose glycolic acid, sodium salt; Cellulose sodium glycolate; Cellulose, carboxymethyl ether sodium salt; Sodium carboxymethylcellulose.

PREPARATION: cellulose fiber with sodium hydroxide and chloroacetic acid.

PHYSICAL AND CHEMICAL PROPERTIES

PHYSICAL FORM: free flowing white to off-white powder

POLYMER FORM: linear

MELTING POINT: 159

SOLUBILITY: soluble

DISPERSION IN WATER: 7 - 10 (1% sol.)

DEGRADATION TEMPERATURE: > 300°C

ECOTOXICITY: Health: 1; Flammability: 3; Reactivity: 0

STABILITY: Stable under ordinary conditions

APPLICATIONS

CMC is used primarily in foods, drugs and cosmetics as a viscosifier, emulsion stabilizer, thickener and to improve texture. The main applications of technical grade are in textile warp-sizing and paper processing. CMC is also used in detergent as an antideposition agent; textile warp-sizing aid; adhesives; latex paints and polishes.

VALS SPECIFICATION

DETERGENT APPROXIMATE

PREPARATION: white to off-white powder

DISPERSION: 30cps. max (1% sol.)

PH: 5 - 9 (1% sol.)

STABILITY: 10.0% max

IMPROVEMENT

FRAC1: 100

FRAC2: 100

FRAC3: 100

FRAC4: 100

FRAC5: 100

FRAC6: 100

FRAC7: 100

FRAC8: 100

FRAC9: 100

FRAC10: 100

FRAC11: 100

FRAC12: 100

FRAC13: 100

FRAC14: 100

FRAC15: 100

FRAC16: 100

FRAC17: 100

FRAC18: 100

FRAC19: 100

FRAC20: 100

FRAC21: 100

FRAC22: 100

FRAC23: 100

FRAC24: 100

FRAC25: 100

FRAC26: 100

FRAC27: 100

FRAC28: 100

FRAC29: 100

FRAC30: 100

FRAC31: 100

FRAC32: 100

FRAC33: 100

FRAC34: 100

FRAC35: 100

FRAC36: 100

FRAC37: 100

FRAC38: 100

FRAC39: 100

FRAC40: 100

FRAC41: 100

FRAC42: 100

FRAC43: 100

FRAC44: 100

FRAC45: 100

FRAC46: 100

FRAC47: 100

FRAC48: 100

FRAC49: 100

FRAC50: 100

FRAC51: 100

FRAC52: 100

FRAC53: 100

FRAC54: 100

FRAC55: 100

FRAC56: 100

FRAC57: 100

FRAC58: 100

FRAC59: 100

FRAC60: 100

FRAC61: 100

FRAC62: 100

FRAC63: 100

FRAC64: 100

FRAC65: 100

FRAC66: 100

FRAC67: 100

FRAC68: 100

FRAC69: 100

FRAC70: 100

FRAC71: 100

FRAC72: 100

FRAC73: 100

FRAC74: 100

FRAC75: 100

FRAC76: 100

FRAC77: 100

FRAC78: 100

FRAC79: 100

FRAC80: 100

FRAC81: 100

FRAC82: 100

FRAC83: 100

FRAC84: 100

FRAC85: 100

FRAC86: 100

FRAC87: 100

FRAC88: 100

FRAC89: 100

FRAC90: 100

FRAC91: 100

FRAC92: 100

FRAC93: 100

FRAC94: 100

FRAC95: 100

FRAC96: 100

FRAC97: 100

FRAC98: 100

FRAC99: 100

FRAC100: 100

FRAC101: 100

FRAC102: 100

FRAC103: 100

FRAC104: 100

FRAC105: 100

FRAC106: 100

FRAC107: 100

FRAC108: 100

FRAC109: 100

FRAC110: 100

FRAC111: 100

FRAC112: 100

FRAC113: 100

FRAC114: 100

FRAC115: 100

FRAC116: 100

FRAC117: 100

FRAC118: 100

FRAC119: 100

FRAC120: 100

FRAC121: 100

FRAC122: 100

FRAC123: 100

FRAC124: 100

FRAC125: 100

FRAC126: 100

FRAC127: 100

FRAC128: 100

FRAC129: 100

FRAC130: 100

FRAC131: 100

FRAC132: 100

FRAC133: 100

FRAC134: 100

FRAC135: 100

FRAC136: 100

FRAC137: 100

FRAC138: 100

FRAC139: 100

FRAC140: 100

FRAC141: 100

FRAC142: 100

FRAC143: 100

FRAC144: 100

FRAC145: 100

FRAC146: 100

FRAC147: 100

FRAC148: 100

FRAC149: 100

FRAC150: 100

FRAC151: 100

FRAC152: 100

FRAC153: 100

FRAC154: 100

FRAC155: 100

FRAC156: 100

FRAC157: 100

FRAC158: 100

FRAC159: 100

FRAC160: 100

FRAC161: 100

FRAC162: 100

FRAC163: 100

FRAC164: 100

FRAC165: 100

FRAC166: 100

FRAC167: 100

FRAC168: 100

FRAC169: 100

FRAC170: 100

FRAC171: 100

FRAC172: 100

FRAC173: 100

FRAC174: 100

FRAC175: 100

FRAC176: 100

FRAC177: 100

FRAC178: 100

FRAC179: 100

FRAC180: 100

FRAC181: 100

FRAC182: 100

FRAC183: 100

FRAC184: 100

FRAC185: 100

FRAC186: 100

FRAC187: 100

FRAC188: 100

FRAC189: 100

FRAC190: 100

FRAC191: 100

FRAC192: 100

FRAC193: 100

FRAC194: 100

FRAC195: 100

FRAC196: 100

FRAC197: 100

FRAC198: 100

FRAC199: 100

FRAC200: 100

FRAC201: 100

FRAC202: 100

FRAC203: 100

FRAC204: 100

FRAC205: 100

FRAC206: 100

FRAC207: 100

FRAC208: 100

FRAC209: 100

FRAC210: 100

FRAC211: 100

FRAC212: 100

FRAC213: 100

FRAC214: 100

FRAC215: 100

FRAC216: 100

FRAC217: 100

FRAC218: 100

FRAC219: 100

FRAC220: 100

FRAC221: 100

FRAC222: 100

FRAC223: 100

FRAC224: 100

FRAC225: 100

FRAC226: 100

FRAC227: 100

FRAC228: 100

FRAC229: 100

FRAC230: 100

FRAC231: 100

FRAC232: 100

FRAC233: 100

FRAC234: 100

FRAC235: 100

FRAC236: 100

FRAC237: 100

FRAC238: 100

FRAC239: 100

FRAC240: 100

FRAC241: 100

FRAC242: 100

FRAC243: 100

FRAC244: 100

FRAC245: 100

FRAC246: 100

FRAC247: 100

FRAC248: 100

FRAC249: 100

FRAC250: 100

FRAC251: 100

FRAC252: 100

FRAC253: 100

FRAC254: 100

FRAC255: 100

FRAC256: 100

FRAC257: 100

FRAC258: 100

FRAC259: 100

FRAC260: 100

FRAC261: 100

FRAC262: 100

FRAC263: 100

FRAC264: 100

FRAC265: 100

FRAC266: 100

FRAC267: 100

FRAC268: 100

FRAC269: 100

FRAC270: 100

FRAC271: 100

FRAC272: 100

FRAC273: 100

FRAC274: 100

FRAC275: 100

FRAC276: 100

FRAC277: 100

FRAC278: 100

FRAC279: 100

FRAC280: 100

FRAC281: 100

FRAC282: 100

FRAC283: 100

FRAC284: 100

FRAC285: 100

FRAC286: 100

FRAC287: 100

FRAC288: 100

FRAC289: 100

FRAC290: 100

FRAC291: 100

FRAC292: 100

FRAC293: 100

FRAC294: 100

FRAC295: 100

FRAC296: 100

FRAC297: 100

FRAC298: 100

FRAC299: 100

FRAC300: 100

FRAC301: 100

FRAC302: 100

FRAC303: 100

FRAC304: 100

FRAC305: 100

FRAC306: 100

FRAC307: 100

FRAC308: 100

FRAC309: 100

FRAC310: 100

FRAC311: 100

FRAC312: 100

FRAC313: 100

FRAC314: 100

FRAC315: 100

FRAC316: 100

FRAC317: 100

FRAC318: 100

FRAC319: 100

FRAC320: 100

FRAC321: 100

FRAC322: 100

FRAC323: 100

FRAC324: 100

FRAC325: 100

FRAC326: 100

FRAC327: 100

FRAC328: 100

FRAC329: 100

FRAC330: 100

FRAC331: 100

FRAC332: 100

FRAC333: 100

FRAC334: 100

FRAC335: 100

FRAC336: 100

FRAC337: 100

FRAC338: 100

FRAC339: 100

FRAC340: 100

FRAC341: 100

FRAC342: 100

FRAC343: 100

FRAC344: 100

FRAC345: 100

FRAC346: 100

FRAC347: 100

FRAC348: 100

FRAC349: 100

FRAC350: 100

FRAC351: 100

FRAC352: 100

FRAC353: 100

FRAC354: 100

FRAC355: 100

FRAC356: 100

FRAC357: 100

FRAC358: 100

FRAC359: 100

FRAC360: 100

FRAC361: 100

FRAC362: 100

FRAC363: 100

FRAC364: 100

FRAC365: 100

FRAC366: 100

FRAC367: 100

FRAC368: 100

FRAC369: 100

FRAC370: 100

FRAC371: 100

FRAC372: 100

FRAC373: 100

FRAC374: 100

FRAC375: 100

FRAC376: 100

FRAC377: 100

FRAC378: 100

FRAC379: 100

FRAC380: 100

FRAC381: 100

FRAC382: 100

FRAC383: 100

FRAC384: 100

FRAC385: 100

FRAC386: 100

FRAC387: 100

FRAC388: 100

FRAC389: 100

FRAC390: 100

FRAC391: 100

FRAC392: 100

FRAC393: 100

FRAC394: 100

FRAC395: 100

FRAC396: 100

FRAC397: 100

FRAC398: 100

FRAC399: 100

FRAC400: 100

FRAC401: 100

FRAC402: 100

FRAC403: 100

FRAC404: 100

FRAC405: 100

FRAC406: 100

FRAC407: 100

FRAC408: 100

FRAC409: 100

FRAC410: 100

FRAC411: 100

FRAC412: 100

FRAC413: 100

FRAC414: 100

FRAC415: 100

FRAC416: 100

FRAC417: 100

FRAC418: 100

FRAC419: 100

FRAC420: 100

FRAC421: 100

FRAC422: 100

FRAC423: 100

FRAC424: 100

FRAC425: 100

FRAC426: 100

FRAC427: 100

FRAC428: 100

FRAC429: 100

FRAC430: 100

FRAC431: 100

FRAC432: 100

FRAC433: 100

FRAC434: 100

FRAC435: 100

FRAC436: 100

FRAC437: 100

FRAC438: 100

FRAC439: 100

FRAC440: 100

FRAC441: 100

FRAC442: 100

FRAC443: 100

FRAC444: 100

FRAC445: 100

FRAC446: 100

FRAC447: 100

FRAC448: 100

FRAC449: 100

FRAC450: 100

FRAC451: 100

FRAC452: 100

FRAC453: 100

FRAC454: 100

FRAC455: 100

FRAC456: 100

FRAC457: 100

FRAC458: 100

FRAC459: 100

FRAC460: 100

FRAC461: 100

FRAC462: 100

FRAC463: 100

FRAC464: 100

FRAC465: 100

FRAC466: 100

FRAC467: 100

FRAC468: 100

FRAC469: 100

FRAC470: 100

FRAC471: 100

FRAC472: 100

FRAC473: 100

FRAC474: 100

FRAC475: 100

FRAC476: 100

FRAC477: 100

FRAC478: 100

FRAC479: 100

FRAC480: 100

FRAC481: 100

FRAC482: 100

FRAC483: 100

FRAC484: 100

FRAC485: 100

FRAC486: 100

FRAC487: 100

FRAC488: 100

FRAC489: 100

FRAC490: 100

FRAC491: 100

FRAC492: 100

FRAC493: 100

FRAC494: 100

FRAC495: 100

FRAC496: 100

FRAC497: 100

FRAC498: 100

FRAC499: 100

FRAC500: 100

FRAC501: 100

FRAC502: 100

FRAC503: 100

FRAC504: 100

FRAC505: 100

FRAC506: 100

FRAC507: 100

FRAC508: 100

FRAC509: 100

FRAC510: 100

FRAC511: 100

FRAC512: 100

FRAC513: 100

FRAC514: 100

FRAC515: 100

FRAC516: 100

FRAC517: 100

FRAC518: 100

FRAC519: 100

FRAC520: 100

FRAC521: 100

FRAC522: 100

FRAC523: 100

FRAC524: 100

FRAC525: 100

FRAC526: 100

FRAC527: 100

FRAC528: 100

FRAC529: 100

FRAC530: 100

FRAC531: 100

FRAC532: 100

FRAC533: 100

FRAC534: 100

FRAC535: 100

FRAC536: 100

FRAC537: 100

FRAC538: 100

FRAC539: 100

FRAC540: 100

FRAC541: 100

FRAC542: 100

FRAC543: 100

FRAC544: 100

FRAC545: 100

FRAC546: 100

FRAC547: 100

FRAC548: 100

FRAC549: 100

FRAC550: 100

FRAC551: 100

FRAC552: 100

FRAC553: 100

FRAC554: 100

FRAC555: 100

FRAC556: 100

FRAC557: 100

FRAC558: 100

FRAC559: 100

FRAC560: 100

FRAC561: 100

FRAC562: 100

FRAC563: 100

FRAC564: 100

FRAC565: 100

FRAC566: 100

FRAC567: 100

FRAC568: 100

FRAC569: 100

FRAC570: 100

FRAC571: 100

FRAC572: 100

FRAC573: 100

FRAC574: 100

FRAC575: 100

FRAC576: 100

FRAC577: 100

FRAC578: 100

FRAC579: 100

FRAC580: 100

FRAC581: 100

FRAC582: 100

FRAC583: 100

FRAC584: 100

FRAC585: 100

FRAC586: 100

FRAC587: 100

FRAC588: 100

FRAC589: 100

FRAC590: 100

FRAC591: 100

FRAC592: 100

FRAC593: 100

FRAC594: 100

FRAC595: 100

FRAC596: 100

FRAC597: 100

FRAC598: 100

FRAC599: 100

FRAC600: 100

FRAC601: 100

FRAC602: 100

FRAC603: 100

FRAC604: 100

FRAC605: 100

FRAC606: 100

FRAC607: 100

FRAC608: 100

FRAC609: 100

FRAC610: 100

FRAC611: 100

FRAC612: 100

FRAC613: 100

FRAC614: 100

FRAC615: 100

FRAC616: 100

FRAC617: 100

FRAC618: 100

FRAC619: 100

FRAC620: 100

FRAC621: 100

FRAC622: 100

FRAC623: 100

FRAC624: 100

FRAC625: 100

FRAC626: 100

FRAC627: 100

FRAC628: 100

FRAC629: 100

FRAC630: 100

FRAC631: 100

FRAC632: 100

FRAC633: 100

FRAC634: 100

FRAC635: 100

FRAC636: 100

FRAC637: 100

FRAC638: 100

FRAC639: 100

FRAC640: 100

FRAC641: 100

FRAC642: 100

FRAC643: 100

FRAC644: 100

FRAC645: 100

FRAC646: 100

FRAC647: 100

FRAC648: 100

FRAC649: 100

FRAC650: 100

FRAC651: 100

FRAC652: 100

FRAC653: 100

FRAC654: 100

FRAC655: 100

FRAC656: 100

FRAC657: 100

FRAC658: 100

FRAC659: 100

FRAC660: 100

FRAC661: 100

FRAC662: 100

FRAC663: 100

FRAC664: 100

FRAC665: 100

FRAC666: 100

FRAC667: 100

FRAC668: 100

FRAC669: 100

FRAC670: 100

FRAC671: 100

FRAC672: 100

FRAC673: 100

FRAC674: 100

FRAC675: 100

FRAC676: 100

FRAC677: 100

FRAC678: 100

FRAC679: 100

FRAC680: 100

FRAC681: 100

FRAC682: 100

FRAC683: 100

FRAC684: 100

FRAC685: 100

FRAC686: 100

FRAC687: 100

FRAC688: 100

FRAC689: 100

FRAC690: 100

FRAC691: 100

FRAC692: 100

FRAC693: 100

FRAC694: 100

FRAC695: 100

FRAC696: 100

FRAC697: 100

FRAC698: 100

FRAC699: 100

FRAC700: 100

FRAC701: 100

FRAC702: 100

FRAC703: 100

FRAC704: 100

FRAC705: 100

FRAC706: 100

FRAC707: 100

FRAC708: 100

FRAC709: 100

FRAC710: 100

FRAC711: 100

FRAC712